Story

The Full Story

Noritsu spent the post-2016 decade burying one identity — photo-finishing equipment — and building a new one as a three-subsidiary "No.1 / Only 1" manufacturing holding. From FY2022 to FY2024 management's story tightened: a pure manufacturing portfolio, the FY25 mid-term plan hit two years early, then re-raised and hit again one year early. FY2025 introduced the first real friction — a blocked Serato acquisition, U.S. tariffs absorbed into guidance, and a "4th business" hunt that has not yet produced a deal. Credibility on numbers is intact; credibility on what to do next is the open question.

1. The Narrative Arc

No Results

The arc has three movements. FY2021–2022: the "great cleanup" — healthcare (JMDC) cashed out to OMRON, imaging long gone, balance sheet reset. FY2023–2024: execution beat on beat — revenue up ~45% in two years, EBITDA margin from 15% to 23%, the mid-term plan hit twice, once from two years out and once from one year out. FY2025: the first plateau. Revenue barely grows, EBITDA steps down, and the story pivots from delivering the plan to finding the next plan.

**Key inflection:** Feb 14, 2025 — Noritsu simultaneously announced MTMP FY25 beat (a year early) and unveiled MTMP FY30 with a revenue target nearly 2x current revenue and an explicit "4th business" line item. That single day reframes the entire next chapter on whether Iwakiri can do acquisitions as well as he did divestitures.

2. What Management Emphasized — and Then Stopped Emphasizing

Topic frequency across integrated reports, MD&A, and quarterly commentary. Intensity is 0–10, scaled by how often a theme drove the message that year.

Three patterns matter. (1) "No.1 / Only 1" is fading — it was the founding slogan of the reset but is now implied, not repeated. (2) Software/Serato peaked in FY23 and collapsed in FY25 — this is the quietest walk-back in the file, because management did not retract the software ambition so much as stop bringing it up after the regulatory block. (3) The "4th business" theme rose from zero to the dominant message — it is now the biggest promise on the table, replacing "deliver the three cores."

Two themes that never faded: capital efficiency (ROE 10%, ROIC above WACC, DOE 3.5–4%) keeps climbing as the activist-proof language of choice, and U.S. tariffs went from a paragraph in risk factors to a line item in the revised FY25 guidance.

3. Risk Evolution

How the risk section changed year over year, based on risk factors, MD&A, and CEO/CFO commentary.

The risk register moved with real events, not hypothetically. Tariffs climbed from 1 to 10 because they went from a U.S. campaign slogan to a quantified ¥800M–1.4B EBITDA hit in May 2025 guidance. Supply chain / semis collapsed because they normalized. Goodwill risk spiked in FY22 (JLab ~¥6B impairment absorbed during the U.S. rate shock) then de-escalated as rates stabilized. EU battery regulation (2027) appeared from nowhere and is now a real cost driver for JLab.

The new category — M&A integration risk — did not exist in the FY22 register in any concrete form. By FY25 it is implied in every CFO commentary because the "4th business" hunt implies spending ¥60–100B on a company the market cannot yet evaluate.

4. How They Handled Bad News

Three stress tests across the period. Management gets mixed marks — honest about the Serato block and the tariff hit, more defensive on JLab goodwill.

**Serato (DJ software acquisition, announced Aug 2023).** Promised as the software leg of AlphaTheta. Blocked by regulators in 2024. Management did not issue a retraction; the FY2025 integrated report simply notes: *"the company was unable to finalize its acquisition plan for Serato… initiatives for cultivating new growth areas have been carried over to the next fiscal year."* The handling is honest — the target simply moved from "software via M&A" to "software via organic investment and partnerships" (R&D budget raised to ¥8.4B). But the original ¥4B software-revenue promise for FY25 has effectively been dropped without being formally disowned.

**JLab goodwill impairment (FY2022, approx. ¥6B).** Came inside a year of the $370M acquisition, as U.S. rates repriced the discounted cash flows. Management framed it as an accounting consequence of the macro, not an operational miss, and pointed to JLab's subsequent operational turnaround (EBITDA to ¥2.4B by FY24). That framing has aged well — JLab is now contributing, not destroying value — but the reader should remember that a material share of the goodwill was written off within 18 months of purchase.

**Tariff-driven FY25 guidance cut (May 9, 2025).** Revenue trimmed from ¥112.6B to ¥110.7B; operating profit cut roughly 8%; net income cut roughly 9%. The handling here was unusually disciplined — management *refused* to model demand destruction ("demand trend changes are too uncertain to model, so not included"), which is the opposite of a kitchen-sink. They cut for the direct tariff and FX effect only, leaving room for positive surprise. This reads as confident conservatism, not cover.

5. Guidance Track Record

Promises that mattered to valuation or capital allocation, and what actually happened.

No Results

Credibility Score (0–10)

Credibility score: 7 / 10. Management delivered the numeric targets that were in their control (revenue, EBITDA, EPS) ahead of schedule, twice, and on the third pass raised the bar before beating it. That is rare. The misses cluster in a single pattern: capital-efficiency and strategic-mix targets — ROIC 5–6%, software ¥4B, non-US JLab above 30%, Serato integration. These are the parts of the plan that depend on market acceptance, regulatory approval, or operational execution outside Noritsu's own factories.

The score is not a 9 because the most valuation-sensitive promises — ROE 10%, a value-accretive "4th business," and software revenue — are the ones that slipped or are stretched. It is not lower than 7 because the mid-term plan itself, as scored against its own numeric targets, was beaten twice.

6. What the Story Is Now

Noritsu's story has simplified in one way and stretched in another. It has simplified because the hedge-fund-conglomerate framing of 2016–2021 (healthcare + lifestyle + manufacturing + legacy imaging) is gone. What remains is legible: three industrial leaders in narrow niches, one balance sheet, one capital-allocation discipline, and a management team that has hit its own numbers for three years running.

It has stretched because the next chapter — MTMP FY30 — rests on two things that are not yet in evidence: a ¥60–100B "4th business" acquisition that has not happened, and a ROE of 10%+ that would require roughly doubling current capital-efficiency. The Serato block suggests that adjacent-software M&A may be harder than it looked, and the tariff environment narrows the set of industries where Noritsu-style manufacturing ownership still compounds at 20%+ EBITDA margins.

What to believe

Operational delivery on the three cores. Teibow (cash cow), AlphaTheta (dominant global DJ share, hardware demand resilient), JLab (proven U.S. margins) — all three have multi-year track records at roughly 20% EBITDA margins.
Conservative forecasting and transparent guidance. Three upward revisions in FY24; tariff hit absorbed without kitchen-sinking; post-acquisition goodwill written down within 18 months when the math demanded it.
Financial discipline. Net-cash balance sheet, payout ratio held at 40%+ even through the tariff cut, DOE floor added.

What to discount

Software / services as a major growth leg. Serato blocked, no replacement announced, ¥4B FY25 software-revenue target effectively abandoned.
JLab non-US expansion at the original pace. Target was over 30% of mix by FY25; actual is ~17–18%. The ambition remains, but the trajectory slipped.
ROE / ROIC hitting target without the 4th business. The three cores plus share buybacks arithmetically cannot close the 5.1% → 10% gap on organics alone.

The open question

Can Iwakiri acquire as well as he divested? The decade up to 2022 was a cleanup story: sell JMDC at a premium, exit Halmek, exit imaging, raise dividends. Execution was strong. The decade after 2025 is a capital-deployment story: buy a "4th business" for ¥60–100B at a price and quality that lets consolidated ROE reach 10%. That is a strictly harder problem, and nothing in Noritsu's recent history — Serato blocked, JLab goodwill impaired early — is yet proof that the inbound-M&A muscle is as developed as the outbound-divestiture muscle.

**The cleanest way to read the next 12 months:** watch whether any 4th-business transaction is announced, and at what multiple. A deal at a sensible multiple with clear synergy language would confirm the FY30 plan is real. Another year of "carried forward to next fiscal year" would mean MTMP FY30 has silently become aspirational.